论文部分内容阅读
目的观察罗格列酮对糖尿病大鼠血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6(interleukin-6,IL-6)、C-反应蛋白(C-reactive protein,C-RP)、超氧化物歧化酶(superoxide dismutase,SOD)和对早期皮肤改变的影响。方法将大鼠分为正常对照组(C组,n=13)、糖尿病对照组(DC组,n=13)、糖尿病胰岛素治疗组(DI组,n=13)、糖尿病罗格列酮治疗组(DR组,n=13)。建立糖尿病大鼠模型,于第16周末抽取各组大鼠心脏血测定TNF-α、IL-6、C-RP、SOD的水平,并处死取皮肤,进行病理学观察及皮肤全层与真皮厚度测量。结果与C组相比较,DC组IL-6[(135.05±43.39)pg/mlvs(99.92±32.36)pg/ml]、TNF-α[(1.45±0.67)ng/mlvs(0.86±0.60)ng/ml]、C-RP[(3.51±0.62)mg/Lvs(2.54±1.31)mg/L]水平均明显增高(P<0.05)。DI组和DR组则与正常对照组比较无差异;DC组的SOD水平与正常组相比显著降低[(70.71±37.52)U/mlvs(137.76±27.6)U/ml,P<0.01],DI组[(149.96±13.25)U/ml]和DR组[(128.50±38.27)U/ml]与DC组比较显著增高(P<0.01)。测微尺测量表明致糖尿病后16周大鼠皮肤明显变薄,与C、DI、DR组比较有统计学差异(P<0.05,P<0.01)。组织学观察,表皮细胞层次欠清晰,真皮层胶原萎缩、退化变性,皮下脂肪进行性萎缩;DI和DR组未出现明显的组织学改变。结论罗格列酮与胰岛素一样能降低糖尿病大鼠血清炎性介质、升高SOD水平,对糖尿病大鼠早期皮肤病变具有防护作用。
Objective To observe the effect of rosiglitazone on serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and C-reactive protein , C-RP), superoxide dismutase (SOD) and early skin changes. Methods The rats were divided into normal control group (group C, n = 13), diabetic control group (DC group, n = 13), diabetic insulin treatment group (DI group, n = 13) and diabetic rosiglitazone treatment group (DR group, n = 13). At the end of the 16th week, the levels of TNF-α, IL-6, C-RP and SOD in each group of rat heart blood were determined. The skin was sacrificed and pathological examination was performed. The thickness and thickness of the dermis measuring. Results Compared with group C, the levels of IL-6 [(135.05 ± 43.39) pg / ml vs (1.96 ± 0.60) ng / ml vs ml] and C-RP [(3.51 ± 0.62) mg / L vs (2.54 ± 1.31) mg / L] DI group and DR group were no difference compared with the normal control group; the SOD level in DC group was significantly lower than that in the normal group [(70.71 ± 37.52) U / ml vs (137.76 ± 27.6) U / ml, P <0.01] (149.96 ± 13.25) U / ml and DR group [(128.50 ± 38.27) U / ml] were significantly higher than those in DC group (P <0.01). Measurements by micrometer showed that the skin of rats after 16 weeks of diabetes was significantly thinner than that of C, DI and DR groups (P <0.05, P <0.01). Histological observation revealed that the epidermal cell level was not clear, dermal collagen atrophy, degenerative degeneration and subcutaneous fat atrophy. No obvious histological changes were found in DI and DR groups. Conclusions Rosiglitazone, like insulin, can reduce the serum inflammatory mediators and increase the level of SOD in diabetic rats, which has a protective effect on the early skin lesions in diabetic rats.